Hoffmann-La Roche Inc.

Thomas Von Hirschheydt

Edgar Voss

Ulrike Reiff

Wolfgang Von Der Saal

Lothar Kling

Frederick Arthur Brookfield

Hans-Willi Krell

Georg Fertig

Stefan Scheiblich

Michael Brandt

Konrad Honold

Georg Tiefenthaler

Jonathan Gridley

Wolfgang Schaefer

Walter-Gunar Friebe

Edward Andrew Boyd

Birgit Bossenmaier

Michael Edward Prime

Petra Rueger

Manfred Kubbies

Thomas Friess

Manfred Schwaiger

Irene Kolm

Hubert Hertenberger

Raymond Lau

Birgit Weydanz

Timothy Woodcock

Jane Paul

Carl Roeschlaub

Alan Whittle

Rolf Juchem

The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.

Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors

Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. 

Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. 

Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Pyridylsulfonamide derivatives

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Phenylpyridine derivatives

The present invention relates to the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Triazole derivatives

The present invention relates to compounds of formula I wherein R, Rand Rare defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents

Compounds of the general formula (I) are presented which arevaluable therapeutics for the treatment of cancer and cancer related diseases.

Imidazole derivatives and their use as pharmaceutical agents

Compounds of the general formula (I) are presented and are valuable therapeutics for the treatment of cancer and cancer related diseases.

Triarylimidazoles

This invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and cancer related diseases.

2-(2,6-Dichlorophenyl)-Diarylimidazoles

2-(2,6-dichlorophenyl)-diarylimidazoles

Growing community of inventors

Penzberg, Germany

Thomas Von Hirschheydt